TL;DR
A systematic overview of advances reported over 2023–2026 in the anticancer activity of benzimidazole derivatives is provided and can serve as a basis for a further search for novel benzimidazole skeleton-containing anticancer agents.
An inclusive overview of the medicinal chemistry of substituted benzimidazole derivatives with special emphasis on their SAR explanations that influence their cytotoxic activity against diverse human tumor cell lines is provided.
This review outlines synthetic strategies for N-((5-phenyl-1H-pyrazol-3-yl) carbamothioyl) benzamide derivatives, evaluates their biological activity, and discusses structure–activity relationships (SAR).
These findings highlight benzimidazole derivatives, particularly 16a and 17b and their nanoparticle formulations, as promising anticancer candidates, driven primarily by strong cellular potency and favorable safety, substantiating their potential as lead candidates for further optimization and therapeutic development.
A comprehensive overview is provided on the incorporation of the benzimidazole scaffold in FDA‐approved drugs, as well as in clinical trial candidates being developed as protein kinase inhibitors for cancer treatment.
Overall, pyridopyrimidine- and pyridopyrimidinones-based compounds continue to show great promise as potential anticancer agents and further research combining synthetic chemistry, biological studies, and computational approaches may lead to the development of more effective and safer drugs in the future.
This review focuses on the anticancer activities of heterocycle–hydrazone hybrids derived from quinoline, indole, triazole, benzimidazole and isatin, their in vitro cytotoxic results, the proposed mechanism of action of the most active compound, cell death pathway results, docking studies, and cell cycle-arrest results...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
